Home » Topics » BioWorld Science

BioWorld Science
RSS

Dosing of inarigivir stopped in phase II CATALYST program

Dec. 27, 2019

Agios Pharmaceuticals starts recruitment in phase III study of AG-881

Dec. 27, 2019

Pfizer initiates phase I study of PF-07062119

Dec. 27, 2019

RALA as a novel therapeutic target in triple-negative breast cancer

Dec. 27, 2019

Juventas Cell Therapy presents phase I data for CNCT-19 in acute lymphoblastic leukemia

Dec. 27, 2019

Patient enrollment ongoing in phase I study of PF-06940434

Dec. 27, 2019

RBM17 splicing factor maintains leukemia stem cell function in acute myeloid leukemia

Dec. 27, 2019

RAN protein is ALS target

Dec. 27, 2019

Corcept Therapeutics presents glucocorticoid receptor antagonists

Dec. 27, 2019

Idorsia Pharmaceuticals patents lysophosphatidic acid receptor 1 antagonists

Dec. 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...